Download
s12931-021-01807-8.pdf 835,64KB
WeightNameValue
1000 Titel
  • Cost drivers in the pharmacological treatment of interstitial lung disease
1000 Autor/in
  1. Maqhuzu, Phillen Nozibuyiso |
  2. Kreuter, Michael |
  3. Bahmer, Thomas |
  4. Kahn, Nicolas |
  5. Claussen, Martin |
  6. Holle, Rolf |
  7. Schwarzkopf, Larissa |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-08-03
1000 Erschienen in
1000 Quellenangabe
  • 22(1):218
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12931-021-01807-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335870/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Introduction!#!Treatments of interstitial lung diseases (ILDs) mainly focus on disease stabilization and relief of symptoms by managing inflammation or suppressing fibrosis by (in part costly) drugs. To highlight economic burden of drug treatment in different ILD-subtypes we assessed cost trends and therewith-associated drivers.!##!Methods!#!Using data from the German, observational HILDA study we estimated adjusted mean medication costs over 36-month intervals using one- and two-part Generalized Estimating Equation (GEE) regression models with a gamma distribution and log link. Next, we determined factors associated with costs.!##!Results!#!In Idiopathic pulmonary fibrosis (IPF) mean per capita medication costs increased from €1442 before to €11,000€ at the end of study. In non-IPF subtypes, the increase took place at much lower level. Mean per capita ILD-specific medication costs at the end of the study ranged between €487 (other ILD) and €9142 (IPF). At baseline, higher FVC %predicted values were associated with lower medication costs in IPF (-9%) and sarcoidosis (-1%). During follow up higher comorbidity burden escalated costs in progressive fibrosing ILD (PF-ILD) (+52%), sarcoidosis (+60%) and other ILDs (+24%). The effect of disease duration was not uniform, with cost savings in PF-ILD (-8%) and sarcoidosis (-6%), but increased spending in IPF (+11%).!##!Conclusion!#!Pharmacological management of ILD, in particular of IPF imposes a substantial economic burden on the healthcare system. Strategies to reduce comorbidity burden and early treatment may reduce the impact of ILDs on the healthcare system.
1000 Sacherschließung
lokal Lung Diseases, Interstitial/epidemiology [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Longitudinal Studies [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Lung Diseases, Interstitial/economics [MeSH]
lokal Drug Costs/trends [MeSH]
lokal Healthcare spending
lokal Germany/epidemiology [MeSH]
lokal Cohort Studies [MeSH]
lokal Direct costs
lokal ILD management
lokal Lung Diseases, Interstitial/drug therapy [MeSH]
lokal Male [MeSH]
lokal Research
lokal Diffuse parenchymal lung disease
lokal Healthcare expenditure
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-3301-3874|https://frl.publisso.de/adhoc/uri/S3JldXRlciwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/QmFobWVyLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/S2FobiwgTmljb2xhcw==|https://frl.publisso.de/adhoc/uri/Q2xhdXNzZW4sIE1hcnRpbg==|https://frl.publisso.de/adhoc/uri/SG9sbGUsIFJvbGY=|https://frl.publisso.de/adhoc/uri/U2Nod2FyemtvcGYsIExhcmlzc2E=
1000 Hinweis
  • DeepGreen-ID: 91a4de4ed55d48aaa3bd3a67cce2dbab ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6463295.rdf
1000 Erstellt am 2023-11-15T17:46:34.432+0100
1000 Erstellt von 322
1000 beschreibt frl:6463295
1000 Zuletzt bearbeitet Thu Nov 30 21:23:33 CET 2023
1000 Objekt bearb. Thu Nov 30 21:23:33 CET 2023
1000 Vgl. frl:6463295
1000 Oai Id
  1. oai:frl.publisso.de:frl:6463295 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source